Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued on Thursday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Aethlon Medical in a research report on Friday, November 15th.

Aethlon Medical Stock Performance

NASDAQ AEMD opened at $0.57 on Thursday. The business has a fifty day moving average price of $0.41 and a 200 day moving average price of $0.42. The company has a market cap of $7.95 million, a P/E ratio of -0.20 and a beta of 1.79. Aethlon Medical has a one year low of $0.24 and a one year high of $2.35.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.